August 30, 2024 06:00 AM EDTUpdated 11:55 AM

Updated: Alnylam’s new Phase 3 ATTR data bring uncertainty to standard of care ambitions

Ayisha Sharma

News Reporter

Alnylam Pharmaceuticals is continuing to make its case for vutrisiran to become the drug of choice for a heart muscle disease, and while the company …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Updated: Alnylam’s new Phase 3 ATTR data bring uncertainty to standard of care ambitions

Ayisha Sharma

News Reporter

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

SEC probe of Illumina’s Grail deal targets sales forecasts, sources say

Exclusive: A male contraceptive may prevent 99% of pregnancies. Now it’s up to a small biotech to finish testing it

House passes Biosecure Act, sending Chinese biotech ban to Senate

GSK, iTeos rejuvenate struggling TIGIT space with positive Phase 2 Jemperli combo data in lung cancer

#ESMO24 roundup: New data on Amgen’s PRMT5 inhibitor seem lackluster, and Jazz’s HER2 antibody

Adcomm says Intercept's rare liver disease drug should not get full approval

Up­dat­ed: Al­ny­lam’s new Phase 3 AT­TR da­ta bring un­cer­tain­ty to stan­dard of care am­bi­tions

News Reporter

Sign up to read this article for free.

more like this

Viridian Therapeutics

Waltham, MA, USA

Updated: Alnylam’s new Phase 3 ATTR data bring uncertainty to standard of care ambitions